Japanese vs. European View on Amyloid Imaging and Therapy (in collaboration with JSNM)

The advent of FDA approved anti-AB drugs such as Aducanumab and Lecanemab is changing not only the therapeutic prospectives for patients but also the diagnostic flow-charts. However, due to differences in clinical processes and insurance systems in each country, the use of amyloid PET in the diagnostic tree currently varies from country to country. In Europe, CSF diagnosis is often performed first and amyloid PET is performed in selected patients. In Japan, only either CSF diagnosis or amyloid PET is covered by public insurance, so there is a trend toward performing the more expensive PET first. The use of amyloid PET in the setting of anti-AB therapy monitoring, and its exact positioning in the biomarkers  flow-chart is not yet clearly defined. This webinar will present recent findings on the usefulness of amyloid PET and the differences in actual use between Europe and Japan.

Learning Objectives: tba